What is Epoprostenol?

Epoprostenol has two above pharmacological actions: absolute vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation. In animals, the vasodilatory furnishings abate appropriate and larboard ventricular afterload and access cardiac achievement and achievement volume. The aftereffect of epoprostenol on affection amount in animals varies with dose. At low doses, there is vagally advised brudycardia, but at college doses, epoprostenol causes reflex tachycardia in acknowledgment to absolute vasodilation and hypotension. No above furnishings on cardiac advice accept been observed. Added pharmacologic furnishings of epoprostenol in animals cover bronchodilation, inhibition of belly acid secretion, and decreased belly emptying. No accessible actinic appraisal is abundantly acute and specific to appraise the in vivo beastly pharmacokinetics of epoprostenol.

Epoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1α (formed by ad-lib degradation) and 6,15-diketo-13,14-dihydro-PGF1α (enzymatically formed), both of which accept pharmacological action orders of consequence beneath than epoprostenol in beastly analysis systems. Fourteen added accessory metabolites accept been abandoned from urine, advertence that epoprostenol is abundantly metabolized in humans.